Palliative Care Study in Patients With Advanced Cancer
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
A Phase II Double Blind, Placebo Controlled, Randomized, Multicenter Study With AVR118 Solution in Patients With Advanced Malignancies Who Are Not Candidates for Chemotherapy
The purpose of this study is to determine whether patients with advanced cancers who receive
AVR118 solution for injection into the skin can achieve improvement in quality of life.
Based on a study in patients with AIDS, possible benefits may include improved appetite and
strength; weight gain; improved mood; and decreased fatigue. For the first three weeks,
some patients receive AVR118, and others receive placebo (an injection expected to have no
benefits). After three weeks, all patients will be offered the opportunity to take
injections of AVR118.
Advanced cancers are usually debilitating. There are few treatments available for symptoms
of advanced cancers like loss of appetite, decreased strength, fatigue, and change in mood.
A Phase II, double blind study comparing treatment with AVR118 to placebo, followed by an
open label phase treating all patients with AVR118, will enable the Sponsor to gather data
on safety and efficacy of AVR118 in this patient population. Patients aged 18-80 with
advanced cancers (excluding central nervous system [CNS] cancers) who are not receiving
chemotherapy, may be eligible to participate.
We found this trial at
0
sites